• Halozyme CEO Helen Torley exercised options for 1,923 shares at $12.07 on July 8, 2026, lifting direct holdings to 769,703 shares.
• Torley sold 1,923 shares the same day at weighted average prices of $79.28 and $80.19, cutting direct holdings to 767,780 shares.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Halozyme Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001159036-26-000100), on July 09, 2026, and is solely responsible for the information contained therein.